Role of Ruxolitinib in GVHD Treatment
Drs Michael Bishop and John DiPersio comment on clinical implications for the use of ruxolitinib in chronic GVHD and share insights on future directions for GVHD.
Practical Considerations for the Treatment of GVHD
Expert hematologist/oncologists consider combination therapy with ROCK and JAK inhibitors for the treatment of chronic GVHD as well as the use of ibrutinib for disease management.
JAK Inhibitors: Managing Cytopenias in Chronic GVHD
Michael Bishop, MD, and John DiPersio, MD, PhD, discuss pulmonary complications associated with chronic GVHD and the management of cytopenias in patients treated with JAK inhibitors.
Challenges in Managing Chronic GvHD
Drs Michael Bishop and John DiPersio comment on common challenges in measuring response in chronic GvHD and review clinical implication from the REACH3 trial.
Management of Chronic GvHD
Experts in hematology/oncology review factors to consider when approaching the management of chronic graft-versus-host disease.
Third-Line Treatment Approaches for Acute GVHD
John DiPersio, MD, PhD, and Michael Bishop, MD, discuss third-line treatment options for patients with acute and steroid-refractory GVHD.
Approaching Initial Treatment of Chronic GVHD
John DiPersio, MD, PhD, shares his thoughts on approaching initial therapy for chronic GVHD and early intervention with JAK inhibitors.
Frontline Management of GVHD
Michael Bishop, MD, leads the discussion on approaching the first-line management of acute GVHD and the importance of early intervention for patients at risk for the disease.
Risk Factors for GVHD
Expert hematologist-oncologists provide insight on major risk factors for GVHD and associated challenges for treatment.
Role of Early Intervention in GVHD Treatment
Dr John DiPersio discusses an early intervention approach to the management of chronic and acute GVHD.
Overview of Graft vs Host Disease (GVHD)
John DiPersio, MD, PhD, and Michael Bishop, MD, define acute and chronic graft-vs-host disease (GVHD).
Future of GVHD Management: Promising Clinical Trials
Practical Advice: GVHD Management With REACH2 Regimen
REACH2 Trial Regimen Adverse-Event Profile
REACH2 Trial Limitations
Phase III REACH2 Trial: Recent Data Updates
Second-Line Treatment Decision Factors
Multidisciplinary Approach & First-Line Treatment Options
The Ongoing Fight Against Acute GvHD
A key opinion leader provides insight into recent data updates from ongoing trials studying the management of GvHD with promising regimens.
Selecting the Appropriate Patients for Targeted Therapies in Acute Myeloid Leukemia
John DiPersio, MD, PhD, discusses targeted therapies for myeloid malignancies using DARTs, Bites, and antibody–drug conjugates, a topic he presented during the 2019 Society for Hematologic Oncology Annual Meeting.
2 Commerce Drive Cranbury, NJ 08512